(PharmaNewsWire.Com, June 08, 2020 ) The global human liver models market is projected to reach USD 2.56 Billion by 2022 from USD 1.35 Billion in 2017, at a CAGR of 13.6%. The human liver models market is emerging and fragmented in nature with various regional and international players. In 2016, the liver-on-a-chip and liver 3D bioprinting market was dominated by CN Bio (UK) and Organovo Holdings, Inc. (US), respectively.
CN Bio held the leading position in the global liver-on-a-chip market in 2016. The company offers its products and services for drug discovery and drug safety programs. To enhance its production capabilities and applications, the company focuses on adopting inorganic strategies such as collaborations and agreements.
Over the last three years, CN Bio has been a part of six such initiatives that helped the company enhance its presence in this market. For instance, in 2017, CN Bio collaborated with AstraZeneca (UK) to validate a new in vitro tool to predict optimized drug dosing regimens for multi-drug therapies. Furthermore, in 2015, CN Bio collaborated with Alnylam Pharmaceuticals (US) to test and develop therapeutics for liver diseases and infections by using LiverChip, CN Bio’s human liver-on-a-chip platform.
The global liver 3D bioprinting market was dominated by Organovo Holdings, Inc. (US). With its broad product portfolio, Organovo Holdings, Inc. held the leadership position in the global 3D bioprinting market for liver in 2016. Its large market share is attributed to its robust 3D bioprinting portfolio. In addition, the company is focusing on various strategies to expand its product offerings and increase its visibility in the 3D bioprinting market.
In line with this, the company has collaborated with various research organizations and pharmaceutical companies for developing novel products. For instance, in June 2016, Organovo collaborated with the University of California, San Francisco (UCSF) for developing 3D bioprinted tissues, to be used for research on skeletal disease. Similarly, in December 2014, Organovo collaborated with the Yale School of Medicine, Department of Surgery (US) with the aim to develop 3D organ tissues for surgical transplantation research.
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
